Quanterix CEO David Okrongly said they are excited to initiate this technology evaluation with Novartis, one of the world’s leading healthcare companies.
"Through this collaborative project, we hope to leverage the 1000-fold sensitivity improvement of SiMoA technology to develop a novel class of valuable diagnostic tests that will provide greater insight into disease and improve patient outcomes," Okrongly added.